<DOC>
	<DOCNO>NCT02917200</DOCNO>
	<brief_summary>The purpose study evaluate whether different DAV132 dose regimen safe effective capture fecal residue moxifloxacin healthy volunteer .</brief_summary>
	<brief_title>Safety Efficacy Study Different DAV132 Dose Regimens Healthy Volunteers</brief_title>
	<detailed_description>The aim study evaluate performance different DAV132 dose regimens healthy volunteer : - To capture antibiotic residue colon without interfere systemic pharmacokinetics . - To prevent antibiotic-induced change intestinal microbiota . In addition , security DAV132 give different dose regimen 7 day evaluate . This prospective , randomize , control , repeat dos , 12 parallel group , open-label study , blind analytical microbiological evaluation .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Healthy adult ( male female ) , able read write , age 18 60 year old inclusive . 2 . Body mass index ( BMI ) 18.5 30 kg/mÂ² inclusive . 3 . Considered healthy individual accord comprehensive clinical assessment ( detailed medical history full physical examination ) . 4 . Normal vital sign 10min rest supine position : systolic blood pressure 95 140 mmHg inclusive , diastolic blood pressure 45 90 mmHg inclusive heart rate ( pulse rate ) 50 100 bpm inclusive . Out range value accept judge clinically non relevant Investigator . 5 . Normal 12lead ECG 10min rest supine position : PR interval 120 220 msec exclusive , QRS complex &lt; 120 msec , QT interval &lt; 430 msec male &lt; 450 msec female . 6 . Normal hematology blood biochemistry test result . Out range value accept judge clinically non relevant Investigator except potassium magnesium normal value require . 7 . Normal digestive transit , least one daily stool . 8 . Females participate study : either must nonchild bear potential ( surgically sterilize least 3 month prior inclusion , postmenopausal ) . Menopause define 60 year age , 45 60 year age amenorrheic least 2 year plasma FSH level &gt; 30 IU/L ; must negative pregnancy test breastfeeding screening , must use abstinence double contraception method treatment period additional period 2 week end investigational treatment . The accepted double contraception method include use highly effective method birth control ( intrauterine device hormonal contraception ) addition one follow contraceptive option : ( 1 ) condom , ( 2 ) diaphragm cervical/vault cap , ( 3 ) spermicide . 9 . Having give sign write study inform consent prior undertake studyrelated procedure . 10 . Covered French health insurance system . Criteria relate healthy status 1 . Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , bone joint , muscular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease ; sign acute illness . 2 . Any history relevant gastrointestinal disorder within three month prior inclusion . 3 . Frequent headache and/or migraine , recurrent nausea and/or vomit ( event , twice month ) . Subject suffer migraine D1 exclude . 4 . Presence history drug hypersensitivity , allergic disease diagnose treated physician . Criteria specific study 5 . Contraindications fluoroquinolones , risk factor adverse effect associate fluoroquinolones define moxifloxacin Summary Product Characteristics , already include inclusion/exclusion criterion : know hypersensitivity fluoroquinolones , history tendinopathy associate fluoroquinolones , risk factor tendinopathy / know tendon disorder , pregnancy , breast feeding , know history myasthenia gravis , know history / risk factor QT interval prolongation ( include close family history arrhythmic disorder ) . Subjects family history , actual glucose6phosphate dehydrogenase ( G6PDH ) deficiency exclude . Subjects rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption exclude . 6 . Contraindications charcoal , risk factor adverse event associated charcoal already include inclusion/exclusion criterion : know hypersensitivity charcoal , risk gastrointestinal obstruction , perforation hemorrhage , recent digestive tract surgery . 7 . Fecal colonization C. difficile . 8 . Recent history hospitalization ( within last 3 month ) . 9 . Any antibiotic administration within last 3 month . 10 . Any vaccination within last 28 day . 11 . Blood donation , regardless volume , within 2 month inclusion study . 12 . Any previous administration medication previous intake herbal product know interfere drug metabolism St John 's Wort within last 14 day , exception hormonal contraception menopausal hormone replacement therapy paracetamol . Criteria associate addiction 13 . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) . 14 . Smoking 5 cigarette equivalent per day ( include nicotinedelivering device patch , gum electronic cigarette ) , unable stop smoking study . 15 . Excessive consumption beverage contain xanthine base ( 4 cup glass per day ) . 16 . Positive result urine drug screen ( amphetamine / methamphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . 17 . Positive alcohol test . Administrative criterion 18 . Any subject , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . 19 . Any subject exclusion period previous biomedical research accord national law , participation clinical trial simultaneously . 20 . Any subject contact case emergency . 21 . Any subject belongs Investigating Center staff . 22 . Subject legal age unable give consent 23 . Subject deprive liberty judicial administrative decision 24 . Subject legal age legal protection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>